Pricing Log in Create free account
Friday 6 November 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

DNTH Healthcare Biotechnology

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.

Revenue
+205.6%
EPS
+16.1%
Free cash flow
−65.9%

Quarter to September 2026, against a year earlier

86.43 3.42 +4.12%
Market cap
$4.6B
P/E
0.0×
Fwd P/E
−21.5×
Dividend yield
—
F-score
2/9
Altman Z
24.31
Beneish M
−4.75
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Dianthus Therapeutics, Inc. (DNTH) Current ratio

Alert me on Current ratio

Dianthus Therapeutics, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 30.0×, up 16.7× from fiscal 2025 (13.3×). Over the past ten years it has ranged from 4.7× (fiscal 2016) to 18.4× (fiscal 2023); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of 5.0× and above the Healthcare sector median of 3.1×.

Current ratio, annual

Embed this chart

Annual newest first

Period Current ratio Change
FY2025 13.3× (12.48%)
FY2024 15.2× (17.38%)
FY2023 18.4× 84.74%
FY2022 10.0× (40.04%)
FY2021 16.6× 25.47%
FY2020 13.3× 24.88%
FY2019 10.6× (23.89%)
FY2018 13.9× 10.03%
FY2017 12.7× 169.10%
FY2016 4.7× —

Quarterly newest first

Period Current ratio Change
Sep 2026 30.0× 15.02%
Jun 2026 26.1× (10.78%)
Mar 2026 29.3× 119.57%
Dec 2025 13.3× (23.20%)
31 more quarters

Against its own ten years

Low 4.7× High 18.4×
Ten-year median 13.3×
Current reading's percentile 60

Current ratio against peers

Company Current ratio
MANE Veradermics Incorporated compare 70.5×
DNTH Dianthus Therapeutics, Inc. 30.0×
CRSP CRISPR Therapeutics AG compare 16.2×
COGT Cogent Biosciences, Inc. compare 13.6×
EWTX Edgewise Therapeutics, Inc. compare 12.3×
ERAS Erasca, Inc. compare 8.3×
DFTX Definium Therapeutics, Inc. compare 6.9×
LEGN Legend Biotech Corporation Sponsored ADR compare 3.0×
TVTX Travere Therapeutics, Inc. compare 3.0×
Biotechnology industry median 5.0×
Healthcare sector median 3.1×
Market median 1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

More on DNTH